Kanishk Kumar: Thalassemia Pipeline 2025 Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared a post on LinkedIn:
”Thalassemia Pipeline 2025: Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Thalassemia, a group of inherited blood disorders causing reduced hemoglobin synthesis and chronic anemia, is advancing with innovative therapies in 2025. The Thalassemia Pipeline features 25+ pharmaceutical firms developing 28+ investigational medications, from gene editing to small molecules, aimed at increasing hemoglobin levels, reducing transfusion dependency, and improving quality of life for patients with varying severity.
Key Developments in Thalassemia Treatment:
Etavopivat by Novo Nordisk, a PKR activator in Phase III, aims to improve red blood cell health and reduce anemia in thalassemia by enhancing oxygen affinity and decreasing hemolysis.
CS-101 by Correct Sequence Therapeutics, a gene editing therapy in Phase I, reactivates fetal hemoglobin production for a potential lifetime cure using the patient’s own stem cells.
Leading Thalassemia Companies include Novo Nordisk , Kind Pharmaceuticals LLC, Correct Sequence Therapeutics , Editas Medicine, San Rocco Therapeutics, Lantu Biopharma, Regeneron , Kanglin Biotec, Shanghai BDgene Co., Ltd., BioRay Pharmaceutical , Celgene, Mabwell , among others.
Promising therapies include Etavopivat, AND017, CS101, among others.
DelveInsight’s comprehensive report on the Thalassemia Pipeline Analysis 2025․՛՛
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 15:59Filippo Cademartiri: Plaque Burden Is the Dominant Determinant of Long-Term Coronary Risk Beyond Stenosis
-
Apr 15, 2026, 15:33Peter Zdziarski: Will Glanzmann Thrombasthenia Patients Be Formally Recognized as Benefiting from SevenFACT?
-
Apr 15, 2026, 15:20Sonal Sonu: Blood Donation Myths in Rural Areas
-
Apr 15, 2026, 15:01Augustina Isioma Ikusemoro: The Most Misunderstood Cause of a Prolonged APTT in the Laboratory
-
Apr 15, 2026, 14:55Donald Correll: Key Risk Factors for Venous Thromboembolism
-
Apr 15, 2026, 14:48Fadwa Said Abdelazim: Is Vaping Really ‘Safer’ for the Blood Than Smoking?
-
Apr 15, 2026, 14:42Augustina Isioma Ikusemoro: An Underrecognized Cause of Severe Thrombocytopenia Following Transfusion
-
Apr 15, 2026, 14:42Caitlin Raymond: Augmented Intelligence Enhancing Human Capability Without Replacement
-
Apr 15, 2026, 14:39Pooja Choradia: Recognizing Pulmonary Embolism in Pregnancy Before It Is Too Late